ArticleBMC pulmonary medicine2026
Practice patterns of pulmonologists regarding extended anticoagulation therapy after pulmonary embolism.
Article in BMC pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesDetermining the optimal duration of anticoagulation after pulmonary embolism remains a clinical challenge. Although guidelines recommend individualized decisions based on recurrence and bleeding risk, no universally accepted algorithm exists. This study aimed to evaluate pulmonologists' practice patterns regarding extended anticoagulation in Türkiye.
methodsA 14 item questionnaire based on current international guidelines on pulmonary embolism management was distributed to pulmonology specialists. The survey collected information on physicians' demographics, preferred duration of extended anticoagulation therapy, anticoagulant choice, use of imaging or laboratory tests when determining treatment duration, and reliance on clinical guidelines. Associations between professional characteristics and clinical decision-making patterns were analyzed using chi-square tests and Fisher's exact tests.
resultsA total of 159 pulmonologists participated in the study. Most physicians (76.1%) preferred extending anticoagulation therapy for an additional three months, and 88.1% reported using bleeding risk assessment tools when determining treatment duration. The most common reasons for extended therapy were high thrombus burden (51.6%), transient or reversible venous thromboembolism risk factors (50.3%), prior thrombolytic therapy (47.2%), and persistent deep vein thrombosis (45.3%). Direct oral anticoagulants were the most frequently preferred agents, with rivaroxaban selected by 74.8% of respondents. More than half of respondents routinely requested imaging or laboratory tests at the third month, most commonly lower extremity venous doppler ultrasonography (61.6%), echocardiography (56.0%), and computed tomography pulmonary angiography (52.2%). Additionally, 67.9% of participants reported that current clinical guidelines were partially sufficient for guiding treatment decisions.
conclusionsConsiderable variability exists in self-reported practice patterns regarding extended anticoagulation after pulmonary embolism among the participating pulmonologists. These findings suggest a perceived need for clearer clinical guidance and more practical integrated risk assessment tools to support treatment decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.